
Please try another search
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Sharon Shacham | 54 | 2020 | Independent Director |
David Berman | 53 | 2021 | Member of Scientific Advisory Board |
Derek Paul DiRocco | 44 | 2021 | Independent Director |
Kristina Masson | 44 | 2018 | Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director |
Michael John Tomsicek | 59 | 2022 | Independent Director |
George Daniel Demetri | 68 | 2021 | Member of Scientific Advisory Board |
Charles M. Baum | 67 | 2023 | Independent Director |
Santhosh Palani | 41 | 2024 | Independent Director |
Timothy A. Yap | 50 | 2021 | Member of Scientific Advisory Board |
Ivana Magovcevic-Liebisch | 58 | 2024 | Independent Director |
David Berman | - | 2021 | Member of Advisory Board |
Ramez N. Eskander | - | 2025 | Member of Scientific Advisory Board |
Robert L. Coleman | 64 | 2025 | Member of Scientific Advisory Board |
Jesper V. Olsen | - | 2021 | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review